<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Gane, Edward J.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Rapid Sustained HCV Viral Load Reductions Achieved with ACH-3102 Plus SOF</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-10</style></pages><abstract><style  face="normal" font="default" size="100%">ACH-3102 is a second-generation hepatitis C virus (HCV) nonstructural 5A (NS5A) protein inhibitor with potent activity against HCV genotype (GT)-1 through GT-6. An ongoing phase 2 open-label study evaluated the safety and efficacy of 8 and 6 weeks of ACH-3102 plus sofosbuvir therapy in treatment-naïve patients with chronic HCV GT-1 infection, as discussed in this article.</style></abstract><number><style face="normal" font="default" size="100%">48</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>